Login / Signup

Biological therapy safety in chronic inflammatory arthropathy patients.

Noemi Martínez-López-de-CastroMiriam Álvarez-PayeroMarisol Samartín-UchaAlicia Martín-VilaGuadalupe Piñeiro-CorralesMaría Rodríguez-RodríguezFrancisco José Maceiras-PanRafael Benito Melero-GonzálezJose María Pego-Reigosa
Published in: European journal of rheumatology (2020)
Over half of the patients with arthropathies on biological therapy can suffer adverse effect during treatment but only 8.5% of these effects are serious. Special vigilance must be paid to patients with a higher number of comorbidities because they are more likely to experience serious adverse effects.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • oxidative stress
  • peritoneal dialysis
  • mesenchymal stem cells
  • cell therapy